Back to Search
FARHAD DANESH, MD
MD
Nephrology Physician
NPI: 1740312412IndividualAccepts Medicare
Specialties, Licenses & Credentials
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
42080(TX)N1843(TX)
CMS Specialties
PrimaryNEPHROLOGY
Education
OTHER
Class of 1989
Research & Publications (20)
Rap1b GTPase ameliorates glucose-induced mitochondrial dysfunction.
PMID 18753253·J Am Soc Nephrol·2008
7-preclinical
Diabetic nephropathy: mechanisms of renal disease progression.
PMID 18156300·Exp Biol Med (Maywood)·2008
6-review
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
PMID 18083785·Diabetes·2008
7-preclinical
Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective.
PMID 17591948·Am J Pathol·2007
6-review
RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin.
PMID 17075836·Arthritis Rheum·2006
8-other
Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes.
PMID 17028260·Am J Physiol Renal Physiol·2006
7-preclinical
HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation.
PMID 16774905·Am J Physiol Renal Physiol·2006
7-preclinical
Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience.
PMID 16330753·Proc Natl Acad Sci U S A·2005
4-observational
Renal-specific oxidoreductase biphasic expression under high glucose ambience during fetal versus neonatal development.
PMID 16164644·Kidney Int·2005
7-preclinical
HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation.
PMID 16160062·FASEB J·2005
7-preclinical
Hyperglycemia: its imminent effects on mammalian nephrogenesis.
PMID 15875217·Pediatr Nephrol·2005
6-review
Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy.
PMID 15840669·Nephrol Dial Transplant·2005
7-preclinical
Effects of statin therapy on the progression of chronic kidney disease.
PMID 15822054·Adv Chronic Kidney Dis·2005
6-review
Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27.
PMID 15213258·J Am Soc Nephrol·2004
7-preclinical
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
PMID 15117885·FASEB J·2004
6-review
Update of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephrogenesis.
PMID 14707006·Am J Physiol Renal Physiol·2004
6-review
Immunomodulatory effects of HMG-CoA reductase inhibitors.
PMID 12894868·Arch Immunol Ther Exp (Warsz)·2003
6-review
Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus.
PMID 12871137·Curr Med Chem·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1740312412
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile